Roles of ITPA and IL28B genotypes in chronic Hepatitis C patients treated with peginterferon plus ribavirin in Tunisian population

Highlights • New HCV therapeutic option not available for all. • Predictive markers of response and toxicity to treatment are needed. • No data on the Tunisian population. • Impact of ITPA and IL28B polymorphisms on treatment response and toxicity in Tunisian population.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical virology 2015-08, Vol.69, p.184-189
Hauptverfasser:	Sghaier, Ikram, Mouelhi, Leila, Gazouani, Ezzedine, Morel, Virginie, Besma, Yacoubi Loueslati, Brochot, Etienne
Format:	Artikel
Sprache:	eng
Schlagworte:	Allergy and Immunology Anemia - epidemiology Antiviral Agents - therapeutic use Drug Therapy, Combination Female Hepacivirus - drug effects Hepacivirus - genetics Hepatitis C Hepatitis C virus Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - genetics Humans IL28B polymorphism Infectious Disease Interferon alpha-2 Interferon-alpha - therapeutic use Interleukins - genetics ITPA polymorphism Male Peginteferon Polyethylene Glycols - therapeutic use Polymorphism, Single Nucleotide Pyrophosphatases - genetics Recombinant Proteins - therapeutic use Ribavirin Ribavirin - therapeutic use Therapy success Treatment Outcome Tunisia - epidemiology Viral Load - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • New HCV therapeutic option not available for all. • Predictive markers of response and toxicity to treatment are needed. • No data on the Tunisian population. • Impact of ITPA and IL28B polymorphisms on treatment response and toxicity in Tunisian population.
ISSN:	1386-6532 1873-5967
DOI:	10.1016/j.jcv.2015.06.102